Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lonvoguran ziclumeran - Intellia Therapeutics

Next Previous
Drug Profile

Lonvoguran ziclumeran - Intellia Therapeutics

Alternative Names: KLKB1 HAE therapeutic - Intellia Therapeutics; lonvo-z; NTLA-2002

Latest Information Update: 22 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intellia Therapeutics
  • Class Gene therapies; Vascular disorder therapies
  • Mechanism of Action Prekallikrein expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary angioedema
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hereditary angioedema

Most Recent Events

  • 15 Jun 2025 Efficacy and adverse events data from a phase I/II trial in Hereditary angioedema released by Intellia Therapeutics
  • 22 Jan 2025 Intellia Therapeutics announces intention to launch NTLA 2002 for Hereditary angioedema in USA in 2027
  • 15 Jan 2025 Phase-III clinical trials in Hereditary angioedema in South Africa, United Kingdom, New Zealand, Netherlands, Germany, France, Australia (IV) (NCT06634420)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top